Knoxville, Tennessee, United States In 2009 was created BPV Capital Management, which is appeared as VC. The main department of described VC is located in the Knoxville. The venture was found in North America in United States.
We also calculated 2 valuable employees in our database.
Among the various public portfolio startups of the fund, we may underline Arvelle Therapeutics For fund there is no match between the country of its foundation and the country of its the most frequent investments - Switzerland. Among the most successful fund investment fields, there is Biotechnology.
The usual cause for the fund is to invest in rounds with 5 partakers. The meaningful sponsors for the fund in investment in the same round are NovaQuest, Life Sciences Partners, H.I.G. BioHealth Partners.
The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2019. The usual things for fund are deals in the range of more than 100 millions dollars.
Related Funds
| Fund Name | Location |
| Bering Waters Ventures | - |
| Cox Enterprises | Atlanta, Georgia, United States |
| D20 Capital | California, San Francisco, United States |
| Digicel | Jamaica, Kingston, Saint Andrew |
| Elmspring Accelerator | Chicago, Illinois, United States |
| Epicenter Technology | India, Maharashtra, Mumbai |
| Europeatweb | - |
| Gigaom | California, San Francisco, United States |
| Hermitage Asset Management | - |
| Juesheng.com | China, Dongcheng, Shaanxi |
| Kosciuszko Holdings | - |
| LD Captial Culture Investment | Beijing, Beijing, China |
| maaiiconnect | China, Hong Kong, Kowloon |
| Makerpad | Cardiff, United Kingdom, Wales |
| Safa Partners | New York, New York, United States |
| Shanghai Lanting Touzi | China, Shanghai, Xuhui |
| The Andan Foundation | Obwalden, Sarnen, Switzerland |
| Trestle Ventures | Exton, Pennsylvania, United States |
| xross | Chiyoda, Japan |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Arvelle Therapeutics | $42M | 27 May 2020 | Basel, Basel-City, Switzerland | ||
Arvelle Therapeutics | $196M | 18 Feb 2019 | Basel, Basel-City, Switzerland |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Arvelle Therapeutics | $42M | 27 May 2020 | Basel, Basel-City, Switzerland | ||
Arvelle Therapeutics | $196M | 18 Feb 2019 | Basel, Basel-City, Switzerland |
